Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

CTA-30X

Alternative Names: CTA-30X, CTA30X
Latest Update: 2025-01-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Cell Therapy

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Acute Lymphoid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTA30X

P1

Withdrawn

Lymphoma, B-Cell

2023-06-30

BHCT-CTA30X-01

P1

Completed

Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2022-12-29

ChiCTR2100043563

N/A

Recruiting

B-Cell Leukemia|Acute Lymphoid Leukemia

2022-12-09

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions